Dear Editor, {#Sec1}
============

Respiratory syncytial virus (RSV) is the single most important cause of acute lower respiratory tract infection (ALRI) in infants, associated with significant morbidity and, sometimes, mortality in industrialized nations \[[@CR1]\]. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants \[[@CR1]\]. The current Italian Guidelines recommend palivizumab prophylaxis for infants of 29--35 weeks gestational age (wGA) and a chronological age ≤ 6 months at the beginning of the epidemic season, in presence of risk conditions predisposing the infant to severe infections and/or need for hospitalization \[[@CR2]\]. These include attendance of the child in a community setting and/or presence of one or more cohabitees younger than 5 years \[[@CR3]\]. However, following the most recent modification by the American Academy of Pediatrics based on American studies on RSV epidemiology \[[@CR4]\], in September 2016, the Italian Drug Agency (AIFA) decided the total financial coverage of the palivizumab prescription to the healthy preterms by the National Health Service, should be limited to the \< 29 wGA group and age ≤ 12 months at the beginning of the RSV epidemic season (RES) \[[@CR5]\]. However, the vulnerability of otherwise healthy premature infants, and most notably in the \< 32 wGA category was demonstrated by an Italian retrospective analysis on RSV-associated hospitalization during the RSV epidemic season, over a 4 year period, when the use of prophylaxis palivizumab was not widespread in premature infants \[[@CR6]\]. Moreover, a recent study on total costs for hospitalizations and emergency room and/or outpatient visits in infants in the first 3 years of life in Lombardy (Italy) showed that extending palivizumab prophylaxis to 29--32 wGA infants appeared to be a cost-effective strategy \[[@CR7]\]. With this background we retrospectively reviewed records from children ≤ 1 years of age admitted, for RSV-induced ALRI at the Gaslini Hospital, over three consecutive RES (2014--2017) (Fig. [1](#Fig1){ref-type="fig"}). The possible impact on the incidence and severity of RSV bronchiolitis after the new prescription limitation was evaluated, comparing the third RES (2016--2017), with the two previous ones.Fig. 1Circulation of respiratory viruses detected by the Liguria regional reference laboratory in the three RSV epidemic seasons (2014--2015, 2015--2016 and 2016--2017): data related to RSV are reported in *green* columns

All the infant included in the study, had a nasal swab positive for RSV. Co-infections were detected only in 4 infants (*Haemophilus influenza*) with a wGA \< 34 weeks. The total number of infants admitted for RSV-induced ALRI in the three RSV epidemic seasons was 366: 137 in the 1th, 109 in the 2nd and 120 in the 3rd season (Fig. [2a](#Fig2){ref-type="fig"}). Only 7.7% of these infants were preterms (29- \< 36 wGA), 6.6% in the 33- \< 36 wGA subgroup and only 1.1% in the 29- \< 33 wGA subgroup. Interestingly, the proportion of preterms admitted tended to increased in the three RES from 6.6%, to 7.3%, and to 9.2%, respectively, for the 29- \< 36 wGA group (Fig. [2b](#Fig2){ref-type="fig"}), and from 5.1% to 6.4% and to 8.3%, respectively, for the 33- \< 36 wGA subgroup (Fig. [2c](#Fig2){ref-type="fig"}). Due to the due to small sample size these increases are not statistically significant. The proportion of the very young infants admitted with a chronological age of \< 6 months tended to increase in the three RSV epidemic seasons from 77.4%, 71.6% and 80.8% (Fig. [3a](#Fig3){ref-type="fig"}), and this tendency was even more evident in the \< 3 months chronological age group (48.2%, to 54.1% and to 63.3%, respectively (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 2Admission for RSV infection in infants. **a** Number of infants admitted in the three RSV epidemic seasons (2014--2015, 2015--2016 and 2016--2017). **b** Proportion of preterms (29- \< 36 wGA) admitted in each RSV epidemic season. **c** Proportion of preterms (33- \< 36 wGA) admitted in each RSV epidemic season Fig. 3Proportion of infants (panel **a** and **b**) or of preterms (panel **c** and **d**) admitted for RSV infection in the three RSV epidemic seasons (2014--2015, 2015--2016 and 2016--2017). **a** and **c** Infants \< 6 months of age; (**b** and **d**). Subgroup of infants \< 3 months of age

This trend was observed also in preterms admitted with a chronological age of \< 6 months (66.7%, 50% and 81.8%, respectively; Fig. [3c](#Fig3){ref-type="fig"}) and in the \< 3 month subgroup (55.6%, 50% and 81.8%, respectively (Fig. [3d](#Fig3){ref-type="fig"}).

The vast majority of the 33- \< 36 wGA infants had a chronological age of \< 6 months at the beginning of the RSV epidemic season and had at least one risk factor \[[@CR3]\]. In addition, 64% of the admitted \< 36 wGA infants were treated with high flow nasal cannula (HFNC) ventilation: 50% of those born at 29- \< 33 wGA and 66.6% of those at 33- \< 36 wGA. In the three RSV epidemic seasons, the proportion of preterms treated with HFNC ventilation was 77.8%, 25.0% and 81.8%, respectively (Fig. [4a](#Fig4){ref-type="fig"}), the numbers being 5, 2, 9 in the 33- \< 36 wGA subgroup (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4Frequency of treatment with high flow nasal cannula (HFNC) ventilation among preterms in the three RSV epidemic seasons (2014--2015, 2015--2016 and 2016--2017). **a** Whole preterm population. **b** The 29- \< 33 wGA subgroup. **c** The 33- \< 36 wGA subgroup

Therefore, the prescription limitation on RSV immunoprophylaxis in preterms was associated in the 2016--2017 RSV epidemic season with: a) a high proportion of admission for the \< 36 wGA infants, the great majority born at 33- \< 36 wGA and with chronological age of \< 6 months; b) a high proportion of preterms treated with HFNC ventilation, mostly in the at 33- \< 36 wGA subgroup. The major limitation of the study is that, since the data were collected in a single tertiary level paediatric hospital, the numbers of preterm infants was very small, precluding a reliable statistical analysis. This is a common problem in these kind of reports since preterms represent only a very small proportion in the general infant population, as shown also in studies that have been cited by the American Academy of Pediatrics in the guidance for palivizumab prophylaxis \[[@CR8], [@CR9]\]. Data collection on national records involving other tertiary level paediatric hospitals could provide a sample size large enough to perform a reliable statistical analysis. However, our results on RSV hospitalization and HFNC treatment clearly highlight the vulnerability of young preterms, especially in this last RSV season and point to a need to reevaluate the role of palivizumab prophylaxis in the \> 29 wGA subpopulation when specific risk factors are present.
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